Co-founded by Dr. Robert Langer, BIND Therapeutics (NASDAQ: BIND) is a publicly traded clinical-stage nanomedicine platform company developing Accurins, its novel targeted therapeutics. BIND is leveraging its Medicinal Nanoengineering® platform to develop a pipeline of Accurins, initially in oncology, as well as Accurins in collaboration with biopharmaceutical companies. BIND’s lead drug candidate, BIND-014, is an Accurin that targets PSMA and contains docetaxel, a clinically-validated and widely used cancer chemotherapy drug. BIND was recognized in 2008 as a “Fierce 15” company by FierceBiotech.
BIND Therapeutics raised a $70M+ IPO in 2013 and was acquired by Pfizer in 2016.